Dandruff treatment with unani formulation
- Conditions
- Seborrhea capitis,
- Registration Number
- CTRI/2025/03/081624
- Lead Sponsor
- Central Council for Research in Unani Medicine
- Brief Summary
Huzaz (pityriasis capitis) also known as dandruff is a prevalant scalp disorder affecting more than half of world adult population. it is considered the mildest from of seborreic dermatitis involving subclinicaal inflammation. in comparison seborreic dermatitis exihibits a more inflammatroy nature on the scalp. Pityriasis capitis is characterized by increased scalp epidermal proliferation, along with itching and redness. It shows varying levels of severity and is more common in men than women. The condition is most frequently observed in adolescents aged 15-24 years and in older adults above 50 years[4]. The causative organism of pityriasis capitis is *Malassezia globosa*, a yeast-like fungus that feeds on scalp, feeding on skin oils. Treatment option for dandruff icluding ointment lotions and shampoo. such as zinc pyrithione, salicylic acid, imidazole derivatives, selenium sulfide, tar derivatives, and ketoconazole. However, these synthetic agents are reported to cause side effects like hair loss, increased scaling, itching, nausea, headache, vomiting, photosensitivity, and even cancer. this highlight the need for expooring alternative treatment modakities, where uanani medicine could play a crucial role in providing aq safe and effective treatment. considering all the factors the present study has been desingned to assess the safty and efficacay of a topical unani formulation cosisting of ab-i chuqandar mixed bura armani in managing hazaz comared to ketoconazole 2%.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 24
- 1 Patients of age group of 15 to 65 years with a clinical diagnosis of adherent dandruff of the scalp.
- 2 Must have active adherent dandruff of the scalp 3 Investigators global assessment (IGA) for pruritis score of at least 1.
- 4 Understand and willing to sign written informed consent in case of adults and written parental assent in case of children wherever applicable.
- 1 Pregnant or lactating women by history.
- 2 History of overt bacterial, viral or fungal infection of the head/neck 3 Patients with history or presence of any serious disease including immunological conditions like HIV, current malignancies, diabetes mellitus.
- Hypertension, etc.
- 4History or presence of compromising dermatosis elsewhere on the skin; 5 Patients with damaged skin of scalp 6 Patients with any skin condition e.g., psoriasis, acne, atopic dermatitis; 7 Patients who had used within 1 month prior to baseline any topical and systemic treatment for scalp diseases.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adherent scalp flaking score (ASFS) Baseline 5th day 9th day and 14th day
- Secondary Outcome Measures
Name Time Method 1 IGA for pruritus on 4 point scale 2 Dermatology life quality index (DLQI)
Trial Locations
- Locations (1)
Luqman unani medical college hospital and research centre
🇮🇳Bijapur, KARNATAKA, India
Luqman unani medical college hospital and research centre🇮🇳Bijapur, KARNATAKA, IndiaMansoori Aliya FatimaPrincipal investigator08591300313mansoorialiya769@gmail.com